- $2.11bn
- $1.69bn
- $1.12bn
Brief: Mabion Signs Deal With Novavax Expanding Cooperation To Analytical Services For Early-Stage Pipeline Projects
Brief: Sanofi Spokesperson Says Nuvaxovid to Be Available Across U.S. for 2026-27 Respiratory Virus Season
US FDA approves updated COVID vaccines for 2026-27 season
US STOCKS-Wall St rises as yields ease, Moderna lifts healthcare stocks
US STOCKS-Wall St rises as yields ease, Moderna lifts healthcare stocks
US STOCKS-Wall St rises as yields ease, Moderna lifts healthcare stocks
U.S. STOCKS ON THE MOVE-ServiceNow, Zoom, US homebuilders
U.S. STOCKS ON THE MOVE-Marvell, Pilgrim's Pride, ServiceNow
Biotech stocks hit record high after Moderna, Merck's melanoma vaccine trial win
Biotech stocks jump after Moderna, Merck's melanoma vaccine succeeds in large trial
U.S. STOCKS ON THE MOVE-Braveheart Bio, Paysign, Hertz Global
Novavax raises annual revenue forecast as licensing bets offset weak vaccine demand (updated)
U.S. STOCKS ON THE MOVE-Ralph Lauren, Sempra, Parker-Hannifin, Lincoln International
Novavax, Inc. reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE- MACOM Technology , Becton Dickinson, Centrus Energy
Novavax climbs after raising annual revenue forecast
Novavax lifts annual revenue forecast as licensing bets offset weak vaccine demand
Novavax Inc expected to post a loss of 39 cents a share - Earnings Preview
FDA advisers recommend COVID vaccines be updated to target current dominant variant (updated)